Filana Therapeutics, Inc.
FLNA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.64
KIRA · Stoqly’s AI analyst, in plain words
- Filana Therapeutics, Inc. lost $91.0M in fiscal 2025.
- Free cash flow was −$32.8M in fiscal 2025, — of revenue.
Market cap
$30.7M
P/E
—
Revenue
—
Net income
−$91.0M
Free cash flow
−$32.8M
Operating margin
—
Filana Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$91.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Filana Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- FILANA THERAPEUTICS, INC.
- CIK
- 0001069530
Filana Therapeutics, Inc. · FLNA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$32.4M | −$76.2M | −$97.2M | −$24.3M | −$91.0M |
| Diluted EPS | −$0.82 | −$1.90 | −$2.32 | −$1.46 | −$1.88 |
| Cash | |||||
| Cash from operations | −$30.2M | −$77.5M | −$82.0M | −$117M | −$32.3M |
| Capital expenditure | $22.2M | $2.7M | $0.4M | $0.1M | $0.6M |
| Free cash flow | −$52.4M | −$80.2M | −$82.4M | −$117M | −$32.8M |
| Share count change | 50.9% | 2.0% | 4.3% | 11.1% | 3.6% |
| Debt and strength | |||||
| Cash and short-term investments | $233M | $201M | $121M | $129M | $95.5M |
| Shareholders' equity | $254M | $228M | $137M | $146M | $74.4M |
| Current ratio | 19.5x | 29.9x | 9.1x | 11.6x | 2.2x |
| Returns and quality | |||||
| Return on equity | −18.7% | −31.7% | −53.3% | −17.2% | −82.7% |
| Return on tangible equity | −12.8% | −33.6% | −70.8% | −16.7% | −122.6% |
| Altman Z'' | 23.1 | 32.2 | 2.3 | 3.7 | −14.3 |
Insiders bought, 12 months
$1.0M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Filana Therapeutics, Inc. · FLNA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.64 a share, the company is worth $30.7M.
Source: SEC EDGAR XBRL filings (CIK 0001069530). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.